Cleveland Clinic research links platelet hyperactivity to glioblastoma progression

Researchers at the Cleveland Clinic have discovered that patients with glioblastoma exhibit hyperactive platelets, which are cells primarily responsible for blood clotting. This hyperactivity appears to suppress the activity of cancer-fighting T cells, potentially contributing to tumor growth and disease progression.

The study, published in Cancer Cell, also highlights a connection between glioblastoma and increased risks of blood-clotting conditions, such as deep vein thrombosis and pulmonary embolism. These thrombotic events are the second leading cause of death among cancer patients and can delay essential cancer therapies.

Preliminary preclinical models suggest that blocking a specific receptor can disrupt this decreased platelet activity, though this effect was observed only in females. Researchers believe hormones may regulate these mechanisms and suggest that targeting overactive platelets could be a new way to improve the immune response to glioblastoma and other cancers, including lung, kidney, and gastrointestinal tumors.